Prolonged Grief Disorder
Recent clinical, regulatory, research and industry developments relating to this disease.
Cross-national analysis of the prevalence of prolonged grief disorder.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q3 2027.
Clinical MilestonesViewHide
- 2026-06-23Psilocybin-Assisted Therapy for Prolonged GriefResults expected Q3 2027
- 2026-06-23ClinicalPsilocybin-Assisted Therapy for Prolonged GriefResults expected Q3 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes1
- Bereavement1
Leading journals1
- Journal of affective disorders1
Leading researchers6
- Comtesse H1
- Dückers MLA1
- Lundorff M1
- Rummel AM1
- Smid GE1
- Spreeuwenberg P1
Affiliations (unnormalised)4
- Aarhus University Hospital1
- ARQ National Psychotrauma Centre1
- Catholic University Eichstaett-Ingolstadt1
- Nivel-Netherlands Institute for Health Services Research1
Reference
Authoritative identity, definition & identifiers.
Severe and disabling grief reactions that do not remit in the 12 months after the death of a significant other. The core of the diagnosis includes persistent yearning or missing the deceased, and preoccupation with the circumstance of the death. (Carmassi, Clinical Handbook of Bereavement and Grief Reactions, 2018)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.